LiDCO launches rapid monitoring system in Europe and US
This article was originally published in Clinica
LiDCO has launched its latest haemodynamic monitor, LiDCOrapid, in the US and EU. The product received US 510(k) clearance and was CE marked for sale in Europe last week. Unlike the older LiDCOplus monitor, which was approved in 2003 and is used in the intensive care unit, LiDCOrapid is designed for the operating theatre. The London, UK company said that LiDCOrapid was quicker to set up and easier to use and interpret, so it was more suited to this setting. LiDCOrapid measures various parameters including heart rate, stroke volume and cardiac output, and blood pressures. It will soon be available in Canada, LiDCO said, and other countries where registration is similar or identical to EU requirements.
You may also be interested in...
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.